The AngioJet Zelante DVT thrombectomy catheter from Boston Scientific has received CE mark and US Food and Drug Administration (FDA) approval for the treatment of deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.
Mubin I Syed, Dayton Interventional Radiology, Dayton, USA, presented on the early results of a pilot study designed is to achieve the collection of safety and efficacy data in patients undergoing left gastric artery embolization for morbid obesity at CIRSE 2015.
Miles Conrad, University of California San Francisco (UCSF), Interventional Radiology section and co-director of the UCSF HHT Centre of Excellence, spoke to Interventional News about a new device being investigated to embolize pulmonary arteriovenous malformations (PAVMs).
Gao-Jun Teng, Department of Radiology, Zhong-Da Hospital, Southeast University, Nanjing, China, presented on a novel stent that is loaded with 125 iodine seeds in malignancies at the “CIRSE meets China” session held at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting in Lisbon, Portugal where he was made a Distinguished Fellow. Teng traced the development of this device from the bench to the bedside.
The first prospective, multicentre study of unselected patients undergoing percutaneous endovascular aortic aneurysm repair (EVAR) confirms previous findings of single-centre studies that the procedure is associated with a high technical success rate when performed by experienced operators.
Paulo Vilares Morgado, Interventional Radiology Unit, University Hospital S João, Porto, Portugal, presented the results of a prospective randomised controlled trial, AGIR (Angio-Seal in Interventional Radiology), at CIRSE 2015.
While presenting on the trials and updates in deep vein thrombosis, Stephen Kee, Professor of Radiology and Chief of Interventional Radiology, UCLA Health System in Los Angeles, speaking at CIRSE 2015, told delegates that there was “an information overload” when Pubmed was searched for “deep vein thrombosis”. There are over 65,000 articles online, he noted, with 42,000 relating to the treatment of the condition, 1,850 dealing with thrombolysis and 474 pertaining to aggressive therapy. “How do we make sense of all this data and what questions really need answering?” Kee asked.
A recent report by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) which reviewed the care received by patients who had a severe gastrointestinal (GI) haemorrhage found that nearly half (49.5%) of the cases had clinical factors identified as leading to less than good care. In 18% of cases organisational factors were identified as contributing to less than good care. Some patients had deficiencies in both clinical and organisational factors.
The embolization of the superior rectal arteries, a procedure termed emborrhoid, has recently been shown to be effective in haemorrhoidal disease for patients who were treated on a compassionate basis.
The first-in-man clinical EVAR case using Lombard’s new IntelliFlex LP delivery system to deploy its Aorfix Endovascular Stent Graft has produced successful outcomes.
The British Society of Interventional Radiology (BSIR) took its campaign to improve the numbers of interventional radiologists in the NHS to Westminster, UK, in November, highlighting that this was a critical issue that needed significant Government focus.
The US FDA (Food and Drug Administration) has issued a safety communication concerning the separation of lubricious coatings from intravascular medical devices. The message aims to make healthcare providers aware of the possibility that hydrophilic and/or hydrophobic coatings may separate from medical devices and cause serious injuries to patients.
Spectranetics has reported that its peripheral atherectomy device—the Turbo-Power laser atherectomy catheter—has received US Food and Drug Administration (FDA) 510(k) clearance for the treatment of in-stent restenosis (ISR).
Two papers presented at the British Society of Interventional Radiology annual meeting (BSIR, 4–6 November, Glasgow, UK) highlighted that prostate artery embolization is a technically demanding procedure that is associated with prolonged radiation exposure to the patient and operator.
The transaction, consisting of an upfront payment of US$70 million and additional payments contingent on regulatory and sales milestones, will expand Boston Scientific’s interventional oncology portfolio with drug-eluting microspheres and spherical embolics.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos